References
- American Cancer Society. Cancer Facts and Figures 2015. 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf).
- Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325–4336.
- Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 Apr 30;113(18):4179–4187.
- Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008 Apr;93(4):594–600.
- NCCN Clinical Practice Guidelines in Oncology. NCCN Clinical Practice Guidelines in Oncology. 2015; Version 1.2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
- Hanaoka K, Suzuki M, Kobayashi T, et al. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer. J Inte Du Cancer. 1999 Jul 19;82(2):226–236.
- Katz MH, Bouvet M, Takimoto S, et al. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res. 2003;63(17):5521–5525.
- Azuma A, Huang P, Matsuda A, et al. 2ʹ-C-cyano-2ʹ-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Molecular Pharmacology. 2001 Apr;59(4):725–731.
- Liu X, Guo Y, Li Y, et al. Molecular basis for G2 arrest induced by 2ʹ-C-cyano-2ʹ-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 2005 Aug 1;65(15):6874–6881.
- Green SR, Choudhary AK, Fleming IN. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. British Journal of Cancer. 2010;103(9):1391–1399.
- Kantarjian H, Garcia-Manero G, O’Brien S, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol: Official J Am Soc Clin Oncology. 2010 Jan 10;28(2):285–291.
- Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. The Lancet Oncology. 2012;13(11):1096–1104.
- Garcia-Manero G, Venugopal SML,P, Maness LJ, et al.. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. J Clin Oncol. 2010;28(15s):suppl; abstr 6528.
- Ravandi F, Kadia TM, Borthakur G, et al. Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. ASH Annual Meeting Abstracts. 2012 November 16;120(21):2630.
- Burnett AK, Russell N, Hills RK, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312–1319.
- Hills RK, Burnett AK. Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood. 2011;118(9):2389–2394.
- Cyclacel Release. Available from: http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=887835. December 16, 2014.